As push to disrupt PD-(L)1 pricing heats up, Checkpoint trumpets a pivotal success

Max Gelman

Senior Editor

The crowded PD-(L)1 market has proven lucrative for biopharma’s earliest entrants like Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, but newer drugs have struggled to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As push to disrupt PD-(L)1 pricing heats up, Checkpoint trumpets a pivotal success

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Eikon Therapeutics raises $351M Series D as lead drug starts Phase 3

Leo Pharma says its yearslong makeover is about to pay off

Merck says Keytruda could be up next for IRA price cuts

Ginkgo uncertain over the future of US government funding, stock drops

Where the money is: The top 100 venture investors in biotech

How AI can address ongoing challenges in the life sciences industry

As push to dis­rupt PD-(L)1 pric­ing heats up, Check­point trum­pets a piv­otal suc­cess

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

As push to disrupt PD-(L)1 pricing heats up, Checkpoint trumpets a pivotal success